Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ.

Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/j.tube.2012.07.003. Epub 2012 Aug 30. Review.

2.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
3.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
4.

Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.

Gruppo V, Johnson CM, Marietta KS, Scherman H, Zink EE, Crick DC, Adams LB, Orme IM, Lenaerts AJ.

Antimicrob Agents Chemother. 2006 Apr;50(4):1245-50.

5.

High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmussen L, Reynolds RC, Secrist JA 3rd, Shindo N, Showe DN, Sosa MI, Suling WJ, White EL.

Tuberculosis (Edinb). 2009 Sep;89(5):334-53. doi: 10.1016/j.tube.2009.05.008. Epub 2009 Sep 15.

6.

[Prospects for development of new antituberculous drugs].

Tomioka H.

Kekkaku. 2002 Aug;77(8):573-84. Japanese.

PMID:
12235850
7.

Programs to facilitate tuberculosis drug discovery: the tuberculosis antimicrobial acquisition and coordinating facility.

Goldman RC, Laughon BE, Reynolds RC, Secrist JA 3rd, Maddry JA, Guié MA, Poffenberger AC, Kwong CA, Ananthan S.

Infect Disord Drug Targets. 2007 Jun;7(2):92-104.

PMID:
17970221
8.

Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.

de Steenwinkel JE, ten Kate MT, de Knegt GJ, Verbrugh HA, van Belkum A, Hernandez-Pando R, Bakker-Woudenberg IA.

Int J Tuberc Lung Dis. 2011 Nov;15(11):1478-84, i. doi: 10.5588/ijtld.11.0012.

PMID:
22008760
9.

Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase.

Andreu N, Zelmer A, Sampson SL, Ikeh M, Bancroft GJ, Schaible UE, Wiles S, Robertson BD.

J Antimicrob Chemother. 2013 Sep;68(9):2118-27. doi: 10.1093/jac/dkt155. Epub 2013 Apr 30.

10.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
11.

New anti-tuberculosis agents amongst known drugs.

Lougheed KE, Taylor DL, Osborne SA, Bryans JS, Buxton RS.

Tuberculosis (Edinb). 2009 Sep;89(5):364-70. doi: 10.1016/j.tube.2009.07.002. Epub 2009 Aug 20.

12.

The search for new sterilizing anti-tuberculosis drugs.

Mitchison DA.

Front Biosci. 2004 May 1;9:1059-72. Review.

PMID:
14977529
13.

Preclinical testing of new drugs for tuberculosis: current challenges.

Lenaerts AJ, Degroote MA, Orme IM.

Trends Microbiol. 2008 Feb;16(2):48-54. doi: 10.1016/j.tim.2007.12.002. Epub 2008 Jan 7.

PMID:
18182291
14.

New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE.

Antimicrob Agents Chemother. 2009 Mar;53(3):849-62. doi: 10.1128/AAC.00749-08. Epub 2008 Dec 15. Review. No abstract available.

15.

Discovery and validation of new antitubercular compounds as potential drug leads and probes.

Goldman RC, Laughon BE.

Tuberculosis (Edinb). 2009 Sep;89(5):331-3. doi: 10.1016/j.tube.2009.07.007. Epub 2009 Aug 28.

16.

A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.

Showalter HD, Denny WA.

Tuberculosis (Edinb). 2008 Aug;88 Suppl 1:S3-17. doi: 10.1016/S1472-9792(08)70032-5. Review.

PMID:
18762151
17.

Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.

Figueiredo R, Moiteiro C, Medeiros MA, da Silva PA, Ramos D, Spies F, Ribeiro MO, Lourenço MC, Júnior IN, Gaspar MM, Cruz ME, Curto MJ, Franzblau SG, Orozco H, Aguilar D, Hernandez-Pando R, Costa MC.

Bioorg Med Chem. 2009 Jan 15;17(2):503-11. doi: 10.1016/j.bmc.2008.12.006. Epub 2008 Dec 10.

PMID:
19119013
18.

Using animal models to develop new treatments for tuberculosis.

Nuermberger E.

Semin Respir Crit Care Med. 2008 Oct;29(5):542-51. doi: 10.1055/s-0028-1085705. Epub 2008 Sep 22. Review.

PMID:
18810687
19.

In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.

Villar R, Vicente E, Solano B, Pérez-Silanes S, Aldana I, Maddry JA, Lenaerts AJ, Franzblau SG, Cho SH, Monge A, Goldman RC.

J Antimicrob Chemother. 2008 Sep;62(3):547-54. doi: 10.1093/jac/dkn214. Epub 2008 May 23.

20.

Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.

Rodrigues-Junior VS, Dos Santos Junior A, Dos Santos AJ, Schneider CZ, Calixto JB, Sousa EH, de França Lopes LG, Souto AA, Basso LA, Santos DS, Campos MM.

Int J Antimicrob Agents. 2012 Aug;40(2):182-5. doi: 10.1016/j.ijantimicag.2012.04.019. Epub 2012 Jun 27.

PMID:
22748570
Items per page

Supplemental Content

Write to the Help Desk